This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Calgary directory, so their courses and email address may be missing. Find their university profile.
Research
Latest papers
A phase I-II study of niacin in patients with newly diagnosed glioblastoma: safety and interim phase II analysis.
Journal of neuro-oncology · 2025
Knockout of the ING5 epigenetic regulator confirms roles in stem cell maintenance and tumor suppression in vivo.
PloS one · 2025
PDGF gene expression and p53 alterations contribute to the biology of diffuse astrocytic gliomas.
NPJ genomic medicine · 2023
Latest funding
- $60,000
Preventing the Emergence of Temozolomide Resistance in Glioblastoma.
CIHR · 2018 · Nominated PI
15 publications.
A phase I-II study of niacin in patients with newly diagnosed glioblastoma: safety and interim phase II analysis.
Roldan Urgoiti G, de Robles P, Tsang RY, Willson M, Ghosh S, Faruqi M, Lim G, Loewen S, Nordal R, Cairncross G, Leckie C, Poon CC, Yong VW
Knockout of the ING5 epigenetic regulator confirms roles in stem cell maintenance and tumor suppression in vivo.
Al Shueili B, Dantas A, Mahe E, Chu TH, Yang Y, Labit E, Kutluberk E, Lasaleta N, Masson A, Omairi H, Ito K, Krawetz RJ, Midha R, Cairncross G, Riabowol K
PDGF gene expression and p53 alterations contribute to the biology of diffuse astrocytic gliomas.
Kumar M, Meode M, Blough M, Cairncross G, Bose P
In vitro modeling of glioblastoma initiation using PDGF-AA and p53-null neural progenitors.
Bohm AK, DePetro J, Binding CE, Gerber A, Chahley N, Berger ND, Ware M, Thomas K, Senapathi U, Bukhari S, Chen C, Chahley E, Grisdale C, Lawn S, Yu Y, Wong R, Shen Y, Omairi H, Mirzaei R, Alshatti N, Pedersen H, Yong W, Weiss S, Chan J, Cimino PJ, Kelly J, Jones S, Holland E, Blough M, Cairncross G
Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells.
Sarkar S, Döring A, Zemp FJ, Silva C, Lun X, Wang X, Kelly J, Hader W, Hamilton M, Mercier P, Dunn JF, Kinniburgh D, van Rooijen N, Robbins S, Forsyth P, Cairncross G, Weiss S, Yong VW
Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells.
Sarkar S, Döring A, Zemp FJ, Silva C, Lun X, Wang X, Kelly J, Hader W, Hamilton M, Mercier P, Dunn JF, Kinniburgh D, van Rooijen N, Robbins S, Forsyth P, Cairncross G, Weiss S, Yong VW
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.
Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M
Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.
Cairncross G, Jenkins R
Methylation status of MGMT gene promoter in meningiomas.
de Robles P, McIntyre J, Kalra S, Roldán G, Cairncross G, Forsyth P, Magliocco T, Hamilton M, Easaw J
Population-based study of medulloblastoma: outcomes in Alberta from 1975 to 1996.
Roldán G, Brasher P, Vecil G, Senger D, Rewcastle B, Cairncross G, Forsyth P, Hamilton M
Preventing the Emergence of Temozolomide Resistance in Glioblastoma.
Principal investigators: Cairncross, Gregory
Keywords: Temozolomide
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
Frequent collaborators
- Biochemistry and Molecular Biology
- Cell Biology and Anatomy
- Medicine
- Pathology and Laboratory Medicine
- Clinical Neurosciences
- Other
Co-authors at University of Calgary, colored by department. Thicker lines mean more shared papers; select anyone to open their profile and their own map.
Samuel Weiss
Cell Biology and Anatomy
3 shared papers, latest 2020
Donna Senger
Medicine
1 shared papers, latest 2008
Karl Riabowol
Biochemistry and Molecular Biology
1 shared papers, latest 2025
Jennifer Chan
Pathology and Laboratory Medicine
1 shared papers, latest 2020
Douglas Demetrick
Biochemistry and Molecular Biology
1 shared papers, latest 2008
Rajiv Midha
Clinical Neurosciences
1 shared papers, latest 2025
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.